Regeneron Pharmaceuticals, Inc. (VIE:REGN)

Market Cap	65.94B -7.5%
Revenue (ttm)	12.22B +1.0%
Net Income	3.84B +2.1%
EPS	35.33 +8.2%
Shares Out	n/a
PE Ratio	17.18
Forward PE	15.76
Dividend	3.14 (0.49%)
Ex-Dividend Date	Nov 20, 2025

Volume	35
Average Volume	5
Open	634.00
Previous Close	627.00
Day's Range	616.00 - 644.00
52-Week Range	420.70 - 700.00
Beta	n/a
RSI	51.40
Earnings Date	Jan 30, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 15,222
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: REGN

Financial Performance

In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.

Financial numbers in USD